160 related articles for article (PubMed ID: 32844906)
1. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.
Rev Inst Med Trop Sao Paulo; 2020; 62():e52err. PubMed ID: 32844906
[No Abstract] [Full Text] [Related]
2. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
3. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.
Frade VP; Simões NS; Couto NRB; Sanches C; Oliveira CDL
Rev Inst Med Trop Sao Paulo; 2020; 62():e52. PubMed ID: 32725057
[TBL] [Abstract][Full Text] [Related]
4. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.
Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R
Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
Morilla MJ; Romero EL
Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
[TBL] [Abstract][Full Text] [Related]
6. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.
Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA
Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394
[TBL] [Abstract][Full Text] [Related]
7. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
[TBL] [Abstract][Full Text] [Related]
8. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
Cevey ÁC; Mirkin GA; Donato M; Rada MJ; Penas FN; Gelpi RJ; Goren NB
Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):378-387. PubMed ID: 29040909
[TBL] [Abstract][Full Text] [Related]
10. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
11. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
13. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
14. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
15. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
[TBL] [Abstract][Full Text] [Related]
16. Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
Losada Galván I; Madrid Pascual O; Herrero-Martínez JM; Pérez-Ayala A; Lizasoain Hernández M
Am J Trop Med Hyg; 2019 Jun; 100(6):1477-1481. PubMed ID: 30938285
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
[TBL] [Abstract][Full Text] [Related]
18. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
[TBL] [Abstract][Full Text] [Related]
19. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
20. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
